STK16-IN-1 is a potent, highly selective ATP competitive STK16 inhibitor with IC50 of 0.295 uM, displays excellent selectivity across the kinome.
STK16-IN-1 treatment results in a reduction in cell number and accumulation of binucleated cells after treatment in MCF-7 cells.
Co-treatment of STK16-IN-1 with chemotherapeutics such as cisplatin, doxorubicin, colchicine, and paclitaxel results in a slight potentiation of the antiproliferative effects of the chemotherapeutics.
